Cocrystal Pharma Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Cocrystal Pharma disminuyan en un 15.1% al año. Se prevé que el BPA disminuya en un 14.4% al año.
Información clave
-15.1%
Tasa de crecimiento de los beneficios
-14.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 23.9% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 19 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation
Oct 18Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19
Oct 11Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21
Aug 15Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans
Aug 14Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK
Aug 08We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
Mar 19Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth
Nov 19We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth
Aug 06Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants
Jun 14We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully
May 05Cocrystal Pharma updates on COVID-19 antiviral development programs
May 03Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%
Mar 13What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?
Jan 24Cocrystal sees 2021 cash burn of $800k a month
Jan 11Cocrystal Pharma to test CDI-45205 against coronaviruses
Dec 22Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?
Dec 20Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | N/A | -26 | N/A | N/A | 1 |
12/31/2025 | N/A | -23 | N/A | N/A | 2 |
12/31/2024 | N/A | -20 | N/A | N/A | 3 |
9/30/2024 | N/A | -19 | N/A | N/A | N/A |
6/30/2024 | N/A | -18 | -14 | -14 | N/A |
3/31/2024 | N/A | -17 | -16 | -16 | N/A |
12/31/2023 | N/A | -18 | -15 | -15 | N/A |
9/30/2023 | N/A | -18 | -16 | -16 | N/A |
6/30/2023 | N/A | -20 | -23 | -22 | N/A |
3/31/2023 | N/A | -40 | -21 | -21 | N/A |
12/31/2022 | N/A | -39 | -22 | -21 | N/A |
9/30/2022 | N/A | -38 | -20 | -19 | N/A |
6/30/2022 | N/A | -36 | -16 | -16 | N/A |
3/31/2022 | N/A | -16 | -15 | -15 | N/A |
12/31/2021 | N/A | -14 | -13 | -13 | N/A |
9/30/2021 | 1 | -12 | -12 | -12 | N/A |
6/30/2021 | 1 | -11 | -10 | -10 | N/A |
3/31/2021 | 2 | -10 | -10 | -9 | N/A |
12/31/2020 | 2 | -10 | -10 | -10 | N/A |
9/30/2020 | 2 | -56 | -9 | -9 | N/A |
6/30/2020 | 2 | -55 | -7 | -7 | N/A |
3/31/2020 | 2 | -53 | -6 | -6 | N/A |
12/31/2019 | 7 | -48 | -2 | -2 | N/A |
9/30/2019 | 6 | -45 | -2 | -2 | N/A |
6/30/2019 | 6 | -45 | -3 | -3 | N/A |
3/31/2019 | 5 | -45 | -4 | -4 | N/A |
12/31/2018 | N/A | -49 | -8 | -8 | N/A |
9/30/2018 | N/A | 0 | -8 | -8 | N/A |
6/30/2018 | N/A | 0 | N/A | -8 | N/A |
3/31/2018 | N/A | 0 | N/A | -7 | N/A |
12/31/2017 | N/A | -1 | N/A | -7 | N/A |
9/30/2017 | N/A | -72 | N/A | -8 | N/A |
6/30/2017 | N/A | -71 | N/A | -9 | N/A |
3/31/2017 | N/A | -73 | N/A | -13 | N/A |
12/31/2016 | N/A | -75 | N/A | -15 | N/A |
9/30/2016 | N/A | -40 | N/A | -15 | N/A |
6/30/2016 | 0 | -38 | N/A | -15 | N/A |
3/31/2016 | 0 | -38 | N/A | -13 | N/A |
12/31/2015 | 0 | -50 | N/A | -10 | N/A |
9/30/2015 | 0 | -22 | N/A | -9 | N/A |
6/30/2015 | 0 | -24 | N/A | -7 | N/A |
3/31/2015 | 0 | -16 | N/A | -6 | N/A |
12/31/2014 | 0 | 0 | N/A | -6 | N/A |
9/30/2014 | N/A | 1 | N/A | -5 | N/A |
6/30/2014 | N/A | 3 | N/A | -5 | N/A |
3/31/2014 | N/A | -3 | N/A | -5 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que COCP siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que COCP siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que COCP siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de COCP crezcan más rápidamente que el mercado de US.
Ingresos de alto crecimiento: Se prevé que COCP no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de COCP se prevé que sea elevada dentro de 3 años.